EGb 761® (Tanakan®)
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Memory Disorders, Age-Related
Conditions
Memory Disorders, Age-Related, Retention Disorders, Cognitive
Trial Timeline
Feb 1, 2002 → Nov 1, 2009
NCT ID
NCT00276510About EGb 761® (Tanakan®)
EGb 761® (Tanakan®) is a approved stage product being developed by Ipsen for Memory Disorders, Age-Related. The current trial status is completed. This product is registered under clinical trial identifier NCT00276510. Target conditions include Memory Disorders, Age-Related, Retention Disorders, Cognitive.
What happened to similar drugs?
3 of 3 similar drugs in Memory Disorders, Age-Related were approved
Approved (3) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00500500 | Phase 2 | Terminated |
| NCT00276341 | Phase 3 | Completed |
| NCT00276510 | Approved | Completed |
Competing Products
8 competing products in Memory Disorders, Age-Related
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 43 |
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 29 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 31 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 43 |
| Levetiracetam, Keppra | UCB | Approved | 43 |
| Piracetam | UCB | Pre-clinical | 26 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 29 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 12 |